2023-04-17 17:06:25
The treatment consists of the administration of coagulation factors, which are essential to correct the blood clotting process which is impaired in those affected. Unlike other drug treatments, clotting factors cannot be administered orally or subcutaneously, but must be delivered directly into the bloodstream by intravenous injection. Prompt treatment with factor VIII or IX is essential when a bleeding episode occurs, in order to correct the blood clotting process and stop the bleeding.
In addition to curative treatment, prophylactic therapy can be given regularly to prevent spontaneous bleeding. This method generally requires the administration of coagulation factors 2 to 3 times per week.
Fortunately, significant progress has been made in treatment. Longer-acting recombinant factors have been developed, allowing one injection per week. In addition, monoclonal agents have been developed, providing the possibility of subcutaneous administration from one to four times a week, which is more convenient for patients.
Finally, gene therapy is also a treatment option for patients with hemophilia B without inhibitors. Although this therapy offers great hopes for the future. The follow-up in relation to this therapy is quite short and therefore follow-up, in particular at the hepatic level, is essential.
1681751799
#Living #hemophilia #daily #fight #defective #coagulation